申请人:British Biotech Pharmaceuticals Limited
公开号:US06127427A1
公开(公告)日:2000-10-03
Compounds of general formula (I) ##STR1## wherein X ia a --CO.sub.2 H, --NH(OH)CHO or --CONHOH group; R.sub.1 is a cylcoalkyl, cycloalkenyl or non-aromatic heterocyclic ring containing up to 3 heteroatoms, any of which may be (i) substituted by one ore more substituents selected from C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, halo, cyano (--CN), --CO.sub.2 H, --CO.sub.2 R, --CONH.sub.2, --CONHR, --CON(R).sub.2, --OH, --OR, oxo-, --SH, --SR, --NHCOR, and --NHCO.sub.2 R wherein R is C.sub.1 -C.sub.6 alkyl or benzyl and/or (ii) fused to a cycloalky or heterocyclic ring; and R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined in specification are matrix metalloproteinase inhibitors.
通用式(I)的化合物 ##STR1## 中,其中X是--CO.sub.2 H,--NH(OH)CHO或--CONHOH基团;R.sub.1是一个含有最多3个杂原子的环烷基,环烯基或非芳香杂环,其中任何一个可能被来自C.sub.1-C.sub.6烷基,C.sub.2-C.sub.6烯基,卤素,氰基(--CN),--CO.sub.2 H,--CO.sub.2 R,--CONH.sub.2,--CONHR,--CON(R).sub.2,--OH,--OR,氧代,--SH,--SR,--NHCOR和--NHCO.sub.2 R中选择的一个或多个取代基取代,其中R是C.sub.1-C.sub.6烷基或苄基和/或(ii)与环烷基或杂环并联;以及R.sub.2,R.sub.3,R.sub.4和R.sub.5如规范中定义的是基质金属蛋白酶抑制剂。